/

RGNX

REGENXBIO Inc.Closed

7.26−0.51 −6.56%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 7.35 +1.19%

Open

7.66

Prev close

7.77

Day range

7.117.69

52-week range

5.4616.19

Volume

1.38M0.93×

Mkt cap

479.26M

P/E ttm

—

Fwd P/E

-2.44

EPS ttm

-3.78

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−55.16%

Price Chart

Yahoo Finance · delayed

RGNXOct 12, 2026O 8.12H 8.29L 7.74C 7.77−0.30 (−3.72%)Vol 2.03M

SMA 509.04
SMA 2009.69

1Y change −28.85% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

RGNX REGENXBIO Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +0.13%
1 month: −8.91%
3 months: −39.06%
6 months: −14.05%
Year to date: −46.04%
1 year: −28.85%

Valuation & ownership

Market cap: 479.26M
Enterprise value: 624.20M
P/E (ttm): —
Forward P/E: -2.44
PEG ratio: —
Price / book: 5.48
Price / sales (ttm): 2.75
EV / EBITDA: -4.20
EPS (ttm): -3.78
EPS (forward): -2.98
Beta (5y monthly): 1.13
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 66.01M
Float: 57.23M
Short % of float: 15.41%
Short ratio (days): 7.07
Held by insiders: 6.55%
Held by institutions: 65.25%
Avg volume (3m): 1.49M
50-day average: 9.04
200-day average: 9.69
52-week change: −28.85%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 44.5
vs 50-day SMA: −14.04%
vs 200-day SMA: −19.80%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 6.94%
Realised vol (20d, ann.): 61.7%
From 52-week high: −52.01%
From 52-week low: +42.44%

ANR

Analyst Consensus

12 analysts

Consensus

Buy

1.58 on a 1 (strong buy) – 5 (sell) scale

Mean target

23.58

+224.84% implied

Low 10.00Median 20.00High 50.00

Recommendation trend

Now10 / 2 / 0
1m ago / 2 /

DES

About REGENXBIO Inc.

Yahoo Finance profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

Sector: Healthcare
Industry: Biotechnology
Employees: 371
Headquarters: Rockville, MD, United States
Website: regenxbio.com
Officers: Mr. Curran M. Simpson M.S. President, CEO & Director
Mr. Patrick J. Christmas II, J.D. Executive VP & Chief Strategy and Legal Officer
Dr. Stephen Pakola M.D.

SEAS

Seasonality · RGNX

2015–2026 · monthly returns

Strongest month Nov +16.50%Weakest month Jan −7.77%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-22.5	-19.0	-7.3	7.0	-21.9	70.9	-19.1	-2.0	-20.7	-3.6			−49.6%
2025	4.4	-18.6	8.8	34.4	-7.9	-7.2	3.7	4.9	8.1	32.3	4.9	7.5	+86.3%
2024	-31.4	41.6	20.8	-27.1	-6.5	-18.5	21.8	-14.2	-14.2	-18.1	15.5	-22.1	−56.9%
2023	2.3	-4.1	-15.0	2.4	-11.0	16.0	-5.0	-6.8	-7.0	-21.7	51.4	-8.0	−20.9%
2022	-19.3	-0.7	26.6	-16.4	-24.2	17.4	27.0	-6.0	-10.4	-10.4	1.0	-5.1	−30.6%
2021	-8.9	-1.0	-16.6	1.7	1.7	10.2	-16.8	-0.1	29.8	-15.5	-9.7	2.2	−27.9%
2020	6.2	-8.1	-19.0	23.0	-5.4	-2.2	-10.1	-7.8	-9.8	4.5	21.1	30.2	+10.7%
2019	4.8	17.7	10.8	-12.1	-14.6	19.4	-13.5	-22.3	3.2	0.3	17.3	-2.1	−2.3%
2018	-19.4	6.2	4.9	25.1	45.1	32.4	-2.0	0.2	7.2	-11.7	-10.1	-30.0	+26.2%
2017	-0.3	-0.5	4.9	8.3	-18.2	15.5	-8.9	26.4	44.8	-9.1	-6.2	18.3	+79.2%
2016	-16.3	-12.7	-11.0	-3.5	18.6	-35.3	2.1	43.3	19.6	12.4	41.3	-16.6	+11.7%
2015										-29.8	55.0	-30.7	−24.6%

INSD

Insider Activity · RGNX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

247.6K shares

Sells, 6 months

73.8K shares

Net shares

+173.8K

Net change in insider shares

+4.20%

Date	Insider	Transaction	Shares	Value
Aug 26, 2026	Ciongoli Gregory AustinDirector	Purchase at price 9.14 - 9.36 per share.	102.6K	$949.38K
Aug 24, 2026	Ciongoli Gregory AustinDirector	Stock Award(Grant) at price 0.00 per share.	15.4K	—
Jul 1, 2026	Pakola Stephen JOfficer	Sale at price 13.64 per share.	2.2K	$29.48K
Jul 1, 2026	Pakola Stephen JOfficer	Conversion of Exercise of derivative security at price 7.86 per share.	2.2K	$16.98K
Jun 30, 2026	Pakola Stephen JOfficer	Sale at price 11.04 - 12.86 per share.	56.3K	$688.76K
Jun 30, 2026	Pakola Stephen JOfficer	Conversion of Exercise of derivative security at price 7.86 per share.	36.7K	$288.66K
Jun 29, 2026	Simpson Curran MChief Executive Officer	Stock Award(Grant) at price 10.18 - 14.40 per share.	2.4K	$28.49K
May 28, 2026	Migausky George VDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 28, 2026	Karabelas Argeris NDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 28, 2026	Tasse DanielDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 28, 2026	Mills Kenneth ThomasDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 28, 2026	Fox Allan MarkDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 28, 2026	Glucksmann Alexandra Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 28, 2026	Zachary Jennifer LDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 28, 2026	Bennett Jean M.D., Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 28, 2026	Stump David CarterDirector	Stock Award(Grant) at price 0.00 per share.	9.8K	—
May 10, 2026	Pakola Stephen JOfficer	Sale at price 11.02 per share.	15.3K	$168.71K
Mar 9, 2026	Pakola Stephen JOfficer	Sale at price 10.35 per share.	5.1K	$53.03K
Jan 26, 2026	Mills Kenneth ThomasDirector	Conversion of Exercise of derivative security at price 13.09 per share.	225K	$2.95M
Jan 5, 2026	Simpson Curran MChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	144.9K	—

13F

Investors Holding RGNX

latest 13F filings of 29 followed managers

Investors holding RGNX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$3.1M	0.00%	256.69K	−16%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

RGNX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

RGNX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About REGENXBIO Inc.

Seasonality · RGNX

Insider Activity · RGNX

Congress Trades · RGNX

Investors Holding RGNX

Investors Holding RGNX

Congress Trades · RGNX

Insider Activity · RGNX

Seasonality · RGNX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About REGENXBIO Inc.

Financial Snapshot

Earnings & Dividends

News